Idiopathic pulmonary fibrosis: the lung-scarring disease with treatments that slow it
Last updated September 3, 2026.
Idiopathic pulmonary fibrosis (IPF) is the progressive lung-scarring disease (the tissue between the air sacs thickening and stiffening: the oxygen struggling to cross), causing the creeping breathlessness and the dry cough, mostly in the over-60s. The idiopathic means the cause unknown, the course is the serious one (the scarring does not reverse), but the two antifibrotic medicines (the pirfenidone and the nintedanib) measurably slow the decline, and the transplant transforms the selected patients' course.
What does it feel like?
The slow onset over the months: the breathlessness on the exertion (the creeping kind: the hills, then the flats), the persistent dry cough (the stubborn, the no-phlegm kind), the fatigue, and the clubbing of the fingertips (the some). The flares (the acute exacerbations: the sudden worsening) are the dangerous kind. The doctor's stethoscope hears the characteristic crackles (the Velcro-kind) at the lung bases.
Why does it happen?
The cause unknown (the idiopathic): the scarring process (the fibroblasts over-laying the matrix after the micro-injuries) running without the identified trigger, with the associations: the smoking history, the age, the male sex, the reflux, and the some family clustering. The other fibrosing lung diseases (the autoimmune, the dust-exposure, the drug kinds) must be excluded first: the IPF is the diagnosis after the others are ruled out.
How is it managed?
- The antifibrotics: the pirfenidone and the nintedanib (the decline slowed by the roughly-half in the trials: the breathing capacity preserved longer: the standard for most).
- The support care: the pulmonary rehabilitation (the fitness-and-technique), the vaccinations, the smoking stopped, the reflux treated, the oxygen when the levels fall, and the palliative-care skills woven in early (the symptom control: not the end-of-life-only kind).
- The transplant for the selected: the lung transplant (the life-changing option for the fitter younger patients: the referral early rather than late: the listing takes the time).
- The exacerbation plan: the sudden worsening treated fast, and the trials-and-registries offered where available.
When is it urgent?
The same-day for the sudden-worse breathlessness, the fever, or the chest pain (the exacerbation-or-infection), and the 911-or-ER for the severe breathlessness at the rest or the blue lips. Pymander's escalation routing is built and tested specifically for this class of decision; see the safety architecture working paper.
What a Pymander AI doctor consult looks like
Illustrative example, not a real member's messages.
Common questions
The websites say 3 to 5 years. Is that my timeline?
The number needs the context it never carries: it is the median from the studies before the antifibrotics existed (the half-lived-longer statistic over the largely-untreated, older-diagnosed groups), and the medians do not describe the individuals (the range around them runs from the months to the decades). The diagnosed-now, treated, center-followed patient is the different population from those studies, and the useful number is yours: the lung-function trajectory on your own tests over the coming year, which your team will track and discuss.
Do the antifibrotic medicines actually work?
The yes-with-the-honest-limit: the pirfenidone and the nintedanib both slow the lung-function decline (the trials show the roughly-halving: the scarring progresses, but at the half-speed, which compounds into the years of the preserved capacity), they do not reverse the existing scarring (nothing yet does), and the side effects are the manageable-with-support kind (the nausea-and-diarrhea for the nintedanib, the sun-sensitivity-and-stomach for the pirfenidone: the dose-adjustments and the tricks the teams know well). The starting-early preserves the most.
Should I stop hiking?
No: the adapting, not the stopping: the fitness is the protective asset in the lung disease (the muscles trained use the oxygen more efficiently: the pulmonary rehabilitation formalizes exactly this), so the hiking continues at the breathlessness-honest pace (the flatter routes, the poles, the rests, the companion), the oxygen if prescribed extends the range, and the exertion-with-the-lung-disease done sensibly is the recommended, not the risky. The activity you stop is the capacity you lose.
Am I too old for a transplant at 68?
Not automatically: the centers assess the biological age and the other conditions (the many programs list the patients into the early-70s for the selected candidates), and the reason for the early-referral is the process length (the evaluation, the optimization, the waiting list: the months-to-longer), so the asking-now while you are the strongest is the right move even if you never need the listing. The transplant is the life-changing option for the right candidate, and the only way to know your candidacy is the assessment.
Is it hereditary? Should my children worry?
The mostly-no: the IPF is the sporadic for most (the smoking history, the reflux, the aging lungs the associations), but the small fraction runs in the families (the familial pulmonary fibrosis: the specific gene variants found in some), so the one case in the family needs no family screening, while the two-plus affected relatives earn the genetics conversation. Your children inherit the asking-the-doctor habit, not the disease, in the usual case.
What should I watch for day to day?
The exacerbation signs (the sudden-worse breathlessness, the fever, the new phlegm: the same-day contact: the flares are the dangerous events and the early treatment matters), the home pulse-oximeter if the team suggests it (the trend, not the panic-single-reading), the vaccinations current (the flu-COVID-pneumonia: the infections hit the scarred lungs hard), and the mood watched (the breathlessness-and-prognosis carry the real anxiety-depression load: the palliative-care-and-support services are the symptom-and-coping experts, brought in early for the quality, not the end).